Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting
Henry J. Henk(Rutgers, The State University of New Jersey), Lien Vo(Bristol-Myers Squibb (United States)), Jack Mardekian(Pfizer (United States)), Kevin Odell(Pfizer (United States)), Prianka Singh(Bristol-Myers Squibb (United States)), Chad Patel, Kenneth Tuell(Bristol-Myers Squibb (United States)), Shalabh Singhal(Integrated BioTherapeutics (United States)), Feng Cao(Air Force Medical University), George H. Sands(Pfizer (United States)), Wilson Tan(Pfizer (United States)), Kwanza Price(Pfizer (United States)), Jeffrey Trocio(Pfizer (United States))
Cited by 2
Related Papers
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
Melatonin Ameliorates the Progression of Atherosclerosis via Mitophagy Activation and NLRP3 Inflammasome Inhibition
|Oxidative Medicine and Cellular Longevity|2018|239
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
|Annals of the Rheumatic Diseases|2022|212
Melatonin facilitates adipose‐derived mesenchymal stem cells to repair the murine infarcted heart<i>via</i>the SIRT1 signaling pathway
|Journal of Pineal Research|2015|116